对艾滋病毒感染者进行的两项为期 5 年的比特拉韦/恩曲他滨/替诺福韦-阿拉非那胺研究:通俗易懂的摘要。

IF 2.5 4区 生物学 Q3 MICROBIOLOGY
Paul E Sax, Jason T Hindman, Hal Martin, David Wohl
{"title":"对艾滋病毒感染者进行的两项为期 5 年的比特拉韦/恩曲他滨/替诺福韦-阿拉非那胺研究:通俗易懂的摘要。","authors":"Paul E Sax, Jason T Hindman, Hal Martin, David Wohl","doi":"10.1080/17460913.2024.2372231","DOIUrl":null,"url":null,"abstract":"<p><strong>What is this summary about?: </strong>This is a plain-language summary of an article that reported on two studies of the medication bictegravir/emtricitabine/tenofovir alafenamide (shortened to B/F/TAF). B/F/TAF is a single pill containing three different drugs used to treat human immunodeficiency virus (known as HIV). The drugs work together to lower the levels of HIV (called viral load) in the body and make the virus undetectable in the blood. Researchers measured whether B/F/TAF was safe and effective when taken over 5 years in over 400 people in 10 countries who had never taken HIV medication before.</p><p><strong>What were the results?: </strong>After 5 years, almost all (99%) of the people who took B/F/TAF had an undetectable viral load. This does not mean that they were cured, but that the levels of HIV were so low that the tests used by researchers could not detect the virus in the blood. CD4 is a type of immune system cell. HIV causes CD4 cell numbers to decrease. On average, the number of CD4 cells increased by more than 300 cells per microliter (cells/μL) of blood over 5 years. This means that the immune system was improving. HIV is able to change its genes to escape the effects of the drugs. This is known as HIV resistance to treatment. Nine people had a viral load high enough to suggest that the drugs might not be working, but no resistance to B/F/TAF was seen. Some people (less than one in three) experienced medical problems thought to be linked to B/F/TAF treatment, known as side effects. The most common side effects were headache, diarrhea, nausea, tiredness (fatigue), dizziness, and difficulty falling or staying asleep (insomnia). On average, people's body weight increased by 3 kg in the first year of taking B/F/TAF. This might be because their general health improved after starting HIV treatment. Weight gained after that time was similar to the level of weight gain expected in the general population. Very few people (less than 1 in 100) stopped taking B/F/TAF because of side effects thought to have been caused by B/F/TAF.</p><p><strong>What do the results mean?: </strong>B/F/TAF was effective at treating HIV in people who had never taken HIV medication before. Most (70%) people were still taking B/F/TAF after 5 years.<b>Clinical Trial Registration:</b> NCT02607930 (Study 1489); NCT02607956 (Study 1490) (ClinicalTrials.gov).</p>","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Two 5-year studies of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: a plain-language summary.\",\"authors\":\"Paul E Sax, Jason T Hindman, Hal Martin, David Wohl\",\"doi\":\"10.1080/17460913.2024.2372231\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>What is this summary about?: </strong>This is a plain-language summary of an article that reported on two studies of the medication bictegravir/emtricitabine/tenofovir alafenamide (shortened to B/F/TAF). B/F/TAF is a single pill containing three different drugs used to treat human immunodeficiency virus (known as HIV). The drugs work together to lower the levels of HIV (called viral load) in the body and make the virus undetectable in the blood. Researchers measured whether B/F/TAF was safe and effective when taken over 5 years in over 400 people in 10 countries who had never taken HIV medication before.</p><p><strong>What were the results?: </strong>After 5 years, almost all (99%) of the people who took B/F/TAF had an undetectable viral load. This does not mean that they were cured, but that the levels of HIV were so low that the tests used by researchers could not detect the virus in the blood. CD4 is a type of immune system cell. HIV causes CD4 cell numbers to decrease. On average, the number of CD4 cells increased by more than 300 cells per microliter (cells/μL) of blood over 5 years. This means that the immune system was improving. HIV is able to change its genes to escape the effects of the drugs. This is known as HIV resistance to treatment. Nine people had a viral load high enough to suggest that the drugs might not be working, but no resistance to B/F/TAF was seen. Some people (less than one in three) experienced medical problems thought to be linked to B/F/TAF treatment, known as side effects. The most common side effects were headache, diarrhea, nausea, tiredness (fatigue), dizziness, and difficulty falling or staying asleep (insomnia). On average, people's body weight increased by 3 kg in the first year of taking B/F/TAF. This might be because their general health improved after starting HIV treatment. Weight gained after that time was similar to the level of weight gain expected in the general population. Very few people (less than 1 in 100) stopped taking B/F/TAF because of side effects thought to have been caused by B/F/TAF.</p><p><strong>What do the results mean?: </strong>B/F/TAF was effective at treating HIV in people who had never taken HIV medication before. Most (70%) people were still taking B/F/TAF after 5 years.<b>Clinical Trial Registration:</b> NCT02607930 (Study 1489); NCT02607956 (Study 1490) (ClinicalTrials.gov).</p>\",\"PeriodicalId\":12773,\"journal\":{\"name\":\"Future microbiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future microbiology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1080/17460913.2024.2372231\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1080/17460913.2024.2372231","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本摘要是关于什么的?:这是一篇文章的通俗摘要,报道了关于比特拉韦/恩曲他滨/替诺福韦-阿拉非那胺(简称B/F/TAF)药物的两项研究。B/F/TAF 是一种含有三种不同药物的单一药片,用于治疗人类免疫缺陷病毒(简称 HIV)。这些药物共同作用,降低人体内 HIV 的水平(称为病毒载量),使血液中检测不到病毒。研究人员对 10 个国家的 400 多名从未服用过艾滋病药物的患者进行了为期 5 年的 B/F/TAF 是否安全有效的测试:5年后,几乎所有(99%)服用 B/F/TAF 的人都检测不到病毒载量。这并不意味着他们已经痊愈,而是艾滋病毒的水平非常低,研究人员使用的检测方法无法检测到血液中的病毒。CD4 是一种免疫系统细胞。艾滋病毒会导致 CD4 细胞数量减少。在 5 年的时间里,平均每微升血液中 CD4 细胞的数量增加了 300 多个。这意味着免疫系统正在改善。艾滋病毒能够改变其基因,以逃避药物的作用。这就是所谓的 HIV 抗药性。有九个人的病毒载量高到足以表明药物可能不起作用,但没有发现对 B/F/TAF 产生抗药性。一些人(不到三分之一)出现了被认为与 B/F/TAF 治疗有关的医疗问题,即所谓的副作用。最常见的副作用是头痛、腹泻、恶心、疲倦(疲劳)、头晕、难以入睡或无法入睡(失眠)。在服用 B/F/TAF 的第一年,人们的体重平均增加了 3 公斤。这可能是因为他们在开始接受艾滋病治疗后总体健康状况有所改善。之后增加的体重与普通人群的预期体重增加水平相似。极少数人(不到百分之一)因认为是 B/F/TAF 引起的副作用而停止服用 B/F/TAF。大多数人(70%)在 5 年后仍在服用 B/F/TAF:临床试验注册:NCT02607930(研究 1489);NCT02607956(研究 1490)(ClinicalTrials.gov)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Two 5-year studies of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: a plain-language summary.

What is this summary about?: This is a plain-language summary of an article that reported on two studies of the medication bictegravir/emtricitabine/tenofovir alafenamide (shortened to B/F/TAF). B/F/TAF is a single pill containing three different drugs used to treat human immunodeficiency virus (known as HIV). The drugs work together to lower the levels of HIV (called viral load) in the body and make the virus undetectable in the blood. Researchers measured whether B/F/TAF was safe and effective when taken over 5 years in over 400 people in 10 countries who had never taken HIV medication before.

What were the results?: After 5 years, almost all (99%) of the people who took B/F/TAF had an undetectable viral load. This does not mean that they were cured, but that the levels of HIV were so low that the tests used by researchers could not detect the virus in the blood. CD4 is a type of immune system cell. HIV causes CD4 cell numbers to decrease. On average, the number of CD4 cells increased by more than 300 cells per microliter (cells/μL) of blood over 5 years. This means that the immune system was improving. HIV is able to change its genes to escape the effects of the drugs. This is known as HIV resistance to treatment. Nine people had a viral load high enough to suggest that the drugs might not be working, but no resistance to B/F/TAF was seen. Some people (less than one in three) experienced medical problems thought to be linked to B/F/TAF treatment, known as side effects. The most common side effects were headache, diarrhea, nausea, tiredness (fatigue), dizziness, and difficulty falling or staying asleep (insomnia). On average, people's body weight increased by 3 kg in the first year of taking B/F/TAF. This might be because their general health improved after starting HIV treatment. Weight gained after that time was similar to the level of weight gain expected in the general population. Very few people (less than 1 in 100) stopped taking B/F/TAF because of side effects thought to have been caused by B/F/TAF.

What do the results mean?: B/F/TAF was effective at treating HIV in people who had never taken HIV medication before. Most (70%) people were still taking B/F/TAF after 5 years.Clinical Trial Registration: NCT02607930 (Study 1489); NCT02607956 (Study 1490) (ClinicalTrials.gov).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future microbiology
Future microbiology 生物-微生物学
CiteScore
4.90
自引率
3.20%
发文量
134
审稿时长
6-12 weeks
期刊介绍: Future Microbiology delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this increasingly important and vast area of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信